Medidata Accelerates Business Transformation with Lisa Moneymaker as Chief Strategy OfficerAugust 13, 2025 at 08:00 AM EDT
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a significant investment in its business transformation, positioning Lisa Moneymaker as the organization's new chief strategy officer. Lisa will now lead the company's Strategy team to advance product innovation, deliver unified AI-driven clinical trial Experiences, and support customers' long-term goals by leveraging research insights and proprietary AI to anticipate market trends. “The Strategy organization signifies our unwavering dedication to implementing innovative solutions, reflecting the belief that a strategy rooted in customer needs and mission is necessary for our success in contributing towards the advancement of the broader industry," stated Anthony Costello, CEO, Medidata. "Lisa’s proven leadership within the field and profound grasp of the intricate relationship between technology and clinical research perfectly align with our strategic imperatives and future vision." Prior to her expanded role, Moneymaker was senior vice president, strategic customer engagement for Medidata. She is a seasoned executive with nearly 25 years of experience leading teams in tech-enabled clinical development and working across pharma, biotech, and medical devices. About Medidata About Dassault Systèmes Contact: Medidata PR Analyst Relations
More NewsView More
Attention Income Investors: This REIT Is on Sale ↗
Today 9:01 EST
Via MarketBeat
Tickers
RKLB
MarketBeat Week in Review – 11/17 - 11/21 ↗
Today 7:00 EST
A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves ↗
November 21, 2025
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|

